Special Pathogens Program, Public Health Agency of Canada, Winnipeg, R3E 3R2, Canada.
Shenzhen Key Laboratory of Pathogen and Immunity, State Key Discipline of Infectious Disease, Shenzhen Third People's Hospital, Shenzhen, 511700, China.
Virol Sin. 2017 Dec;32(6):545-547. doi: 10.1007/s12250-017-4057-9.
Q3G is a natural derivative of quercetin and is already widely used in various foods and drinks. Our results clearly demonstrated that Q3G exerts antiviral activity against ZIKV in both tissue culture and knockout mice, and that post-exposure in vivo treatment with Q3G could have a beneficial effect. In the future, Q3G should be tested in human cell lines (such as Huh-7, HeLa, or K048, a fetal brain neural stem cell line) to provide further data supporting its potential efficacy in humans; in addition, live viral loads or viremia should be tested in treated animals to supplement the survival results observed in this study. Although the treatment regimens will need to be further optimized (i.e., dosage, frequency of treatment, and administration routes), our results support the results of Q3G efficacy studies in nonhuman primates against ZIKV infection. Further studies will also be needed to investigate the mechanism of Q3G antiviral action, in order to obtain valuable insights into the design of novel targets for antiviral therapeutics in the future.
Q3G 是槲皮素的天然衍生物，已广泛应用于各种食品和饮料中。我们的结果清楚地表明，Q3G 在组织培养和基因敲除小鼠中均对 ZIKV 具有抗病毒活性，并且体内暴露后用 Q3G 进行治疗可能具有有益的效果。在未来，应在人细胞系（如 Huh-7、HeLa 或 K048，一种胎儿脑神经干细胞系）中测试 Q3G，以提供更多数据支持其在人类中的潜在疗效；此外，应在接受治疗的动物中测试活病毒载量或病毒血症，以补充本研究中观察到的存活结果。尽管需要进一步优化治疗方案（即剂量、治疗频率和给药途径），但我们的结果支持 Q3G 在非人灵长类动物中针对 ZIKV 感染的疗效研究结果。还需要进一步研究 Q3G 抗病毒作用的机制，以便为未来设计新型抗病毒治疗靶标提供有价值的见解。
